for people ages 18-75 (full criteria)
at San Francisco, California and other locations
study started
completion around



The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

Official Title

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia.


Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, Ataxia, SCA, Spinocerebellar Ataxia, Ataxia, Cerebellar Ataxia, Spinocerebellar Degenerations, Machado-Joseph Disease, troriluzole, BHV-4157


You can join if…

Open to people ages 18-75

  1. Subjects with a known or suspected diagnosis of the following specific hereditary ataxias: SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 and SCA10; currently only enrolling SCA 1, SCA2, SCA3, SCA7, and SCA10 (the cap has been met for SCA6 and SCA8 (on May 31, 2019));
    1. A subject should have a confirmed genotypic diagnosis from a CLIA certified lab (can produce test results); or,
    2. A subject has a family member that has a confirmed genotypic diagnosis from a CLIA certified lab (can produce test results) and must be willing to undergo genetic testing to confirm underlying SCA diagnosis; or,
    3. A subject has a confirmed genotypic diagnosis from a lab that is not CLIA certified and must be willing to undergo genetic testing to confirm underlying SCA diagnosis; or,
    4. A subject has clinical evidence that supports diagnosis of one of the aforementioned SCA genotypes but does not have producible test results from a CLIA certified lab from either a family member or for his or herself and the subject must be willing to undergo such testing to confirm the SCA diagnosis (in this case, site must wait for results of genotypic testing prior to randomization)
  2. Ability to ambulate 8 meters without human assistance (canes and other devices allowed)
  3. Screening f-SARA total score ≥3;
  4. Score of ≥1 on gait subsection of the f-SARA
  5. Determined by the investigator to be medically stable at Baseline/randomization as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing.

You CAN'T join if...

  1. A ≥ 2-point difference on the Modified Functional SARA score between screening and baseline
  2. MMSE score <24
  3. Any medical condition other than one of the hereditary ataxias specified in the inclusion criteria that could predominantly explain or contribute significantly to the subjects' symptoms of ataxia.
  4. A prominent spasticity or dystonia that, in the opinion of the investigator, will compromise the ability of the SARA instrument to assess underlying ataxia severity.
  5. A score of 4 on any individual item (Items 1-4) of the f-SARA
  6. Subjects should be excluded at screening or baseline if medical conditions have arisen or there is a change in disease status that could confound the ability of the SARA to accurately reflect changes in ataxia severity.
  7. Active liver disease or a history of hepatic intolerance to medications that in the investigator's judgment, is medically significant


  • UCSF
    San Francisco California 94158 United States
  • UCLA
    Los Angeles California 90095 United States


in progress, not accepting new patients
Start Date
Completion Date
Biohaven Pharmaceuticals, Inc.
Phase 3 research study
Study Type
About 218 people participating
Last Updated